{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:55:56Z","timestamp":1788616556195,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00330-018-5682-x","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T15:29:03Z","timestamp":1534865343000},"page":"1221-1230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["68Ga-PSMA-PET\/CT in comparison with 18F-fluoride-PET\/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8669-5154","authenticated-orcid":false,"given":"Eva","family":"Dyrberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle W.","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri Hien Viet","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Wirenfeldt","family":"Klausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke B.","family":"L\u00f8gager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik M.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik S.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"5682_CR1","volume-title":"Bone cancer. Primary bone cancers and metastases","author":"FG Herrera","year":"2015","unstructured":"Herrera FG, Tawadros T, Berthold DR (2015) Bone cancer. Primary bone cancers and metastases, 2nd edn. Elsevier, San Diego","edition":"2"},{"key":"5682_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1464-410X.2003.04960.x","volume":"94","author":"R Thurairaja","year":"2004","unstructured":"Thurairaja R, Mcfarlane J, Traill Z, Persad R (2004) State-of-the-art approaches to detecting early bone metastatic spread and changes to bone biology in prostate cancer. BJU Int 94:268\u2013271","journal-title":"BJU Int"},{"key":"5682_CR3","doi-asserted-by":"crossref","DOI":"10.1007\/978-88-470-5316-8","volume-title":"Bone marrow MRI","author":"LA Moulopoulos","year":"2015","unstructured":"Moulopoulos LA, Koutoulidis V (2015) Bone marrow MRI, 1st edn. Springer-Verlag Italia, Milan","edition":"1"},{"key":"5682_CR4","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","volume":"6","author":"LA Kingsley","year":"2007","unstructured":"Kingsley LA, Fournier PGJ, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609\u20132617","journal-title":"Mol Cancer Ther"},{"key":"5682_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-47953-6","volume-title":"The pathophysiologic basis of nuclear medicine","author":"A Elgazaar","year":"2006","unstructured":"Elgazaar A (2006) The pathophysiologic basis of nuclear medicine, 2nd edn. Springer, Berlin Heidelberg","edition":"2"},{"key":"5682_CR6","doi-asserted-by":"publisher","unstructured":"H\u00f8ilund-Carlsen PF, Hess S, Alavi A (2017) Bone marrow and NOT bone metastases is what 21st century diagnostic imaging must focus upon when looking for skeletal metastases. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.117.201848","DOI":"10.2967\/jnumed.117.201848"},{"key":"5682_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618\u2013629","journal-title":"Eur Urol"},{"key":"5682_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","volume":"14","author":"JL Mohler","year":"2016","unstructured":"Mohler JL, Armstrong AJ, Bahnson RR et al (2016) Prostate cancer, version 1.2016. J Natl Compr Canc Netw 14:19\u201330","journal-title":"J Natl Compr Canc Netw"},{"key":"5682_CR9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00259-013-2439-2","volume":"40","author":"I Fogelman","year":"2013","unstructured":"Fogelman I, Blake GM, Cook GJR (2013) The isotope bone scan: we can do better. Eur J Nucl Med Mol Imaging 40:1139\u20131140","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5682_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","volume":"73","author":"S Gillessen","year":"2018","unstructured":"Gillessen S, Attard G, Beer TM et al (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73:178\u2013211","journal-title":"Eur Urol"},{"key":"5682_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-42327-2","volume-title":"Bone metastases from prostate cancer","author":"F Bertoldo","year":"2017","unstructured":"Bertoldo F, Boccardo F, Bombardieri E et al (2017) Bone metastases from prostate cancer, 1st edn. Springer, Cham","edition":"1"},{"key":"5682_CR12","doi-asserted-by":"publisher","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP et al (2017) Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 58:67S\u201376S","journal-title":"J Nucl Med"},{"key":"5682_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, Eiber M (2018) Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 38:200\u2013217","journal-title":"Radiographics"},{"key":"5682_CR14","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81\u201385"},{"key":"5682_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.eururo.2016.01.029","volume":"70","author":"L Evangelista","year":"2016","unstructured":"Evangelista L, Briganti A, Fanti S et al (2016) New clinical indications for (18)F\/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 70:161\u2013175","journal-title":"Eur Urol"},{"key":"5682_CR16","doi-asserted-by":"publisher","unstructured":"Zacho HD, Nielsen JB, Haberkorn U, Stenholt L, Petersen LJ (2017) 68 Ga-PSMA PET\/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging. https:\/\/doi.org\/10.1111\/cpf.12480","DOI":"10.1111\/cpf.12480"},{"key":"5682_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12149-010-0393-7","volume":"24","author":"U Tateishi","year":"2010","unstructured":"Tateishi U, Morita S, Taguri M et al (2010) A meta-analysis of (18)F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med 24:523\u2013531","journal-title":"Ann Nucl Med"},{"key":"5682_CR18","doi-asserted-by":"publisher","unstructured":"Pasoglou V, Michoux N, Larbi A, Van Nieuwenhove S, Lecouvet F (2018) Whole body MRI and oncology: recent major advances. Br J Radiol. https:\/\/doi.org\/10.1259\/bjr.20170664%0A","DOI":"10.1259\/bjr.20170664%0A"},{"key":"5682_CR19","doi-asserted-by":"publisher","unstructured":"Tombal B, Lecouvet F (2012) Modern detection of prostate cancer\u2019s bone metastasis: is the bone scan era over? Adv Urol. https:\/\/doi.org\/10.1155\/2012\/893193","DOI":"10.1155\/2012\/893193"},{"key":"5682_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1148\/radiol.11110474","volume":"261","author":"AR Padhani","year":"2011","unstructured":"Padhani AR, Koh D-M, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261:700\u2013718","journal-title":"Radiology"},{"key":"5682_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1148\/radiol.2015151516","volume":"277","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE et al (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 277:826\u2013832","journal-title":"Radiology"},{"key":"5682_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","volume":"62","author":"FE Lecouvet","year":"2012","unstructured":"Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68\u201375","journal-title":"Eur Urol"},{"key":"5682_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:887\u2013897","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5682_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197\u2013209","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5682_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, Stricker P, Van Leeuwen P et al (2015) Prospective comparison of the detection rate of 18F-fluoromethylcholine and 68Ga-PSMA-HBED PET\/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy. J Nucl Med 56:1185\u20131191","journal-title":"J Nucl Med"},{"key":"5682_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00259-015-3078-6","volume":"42","author":"F Ceci","year":"2015","unstructured":"Ceci F, Uprimny C, Nilica B et al (2015) (68)Ga-PSMA PET\/CT for restaging recurrent prostate cancer: which factors are associated with PET\/CT detection rate? Eur J Nucl Med Mol Imaging 42:1284\u20131294","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5682_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668\u2013674","journal-title":"J Nucl Med"},{"key":"5682_CR28","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","volume":"43","author":"T Pyka","year":"2016","unstructured":"Pyka T, Okamoto S, Dahlbender M et al (2016) Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43:2114\u20132121","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5682_CR29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s00330-017-4994-6","volume":"28","author":"J Janssen","year":"2018","unstructured":"Janssen J, Mei\u00dfner S, Woythal N et al (2018) Comparison of hybrid 68Ga-PSMA-PET\/CT and 99mTc-DPD-SPECT\/CT for the detection of bone metastases in prostate cancer patients: additional value of morphologic information from low dose CT. Eur Radiol 28:610\u2013619","journal-title":"Eur Radiol"},{"key":"5682_CR30","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s00259-016-3350-4","volume":"43","author":"L Evangelista","year":"2016","unstructured":"Evangelista L, Bertoldo F, Boccardo F et al (2016) Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging 43:1546\u20131562","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5682_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2017.03.042","volume":"73","author":"S Woo","year":"2018","unstructured":"Woo S, Suh CH, Kim SY et al (2018) Diagnostic performance of magnetic resonance imaging for the detection of bone metastasis in prostate cancer: a systematic review and meta-analysis. Eur Urol 73:81\u201391","journal-title":"Eur Urol"},{"key":"5682_CR32","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/MNM.0b013e328364918a","volume":"34","author":"M Wondergem","year":"2013","unstructured":"Wondergem M, van der Zant FM, van der Ploeg T, Knol RJJ (2013) A literature review of 18F-fluoride PET\/CT and 18F-choline or 11C-choline PET\/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 34:935\u2013945","journal-title":"Nucl Med Commun"},{"key":"5682_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-319-42327-2_13","volume-title":"Bone metastases from prostate cancer","author":"A Luzzati","year":"2017","unstructured":"Luzzati A, Scotto G, Perrucchini G, Zoccali C (2017) Surgery: treatment of oligometastatic disease. In: Bertoldo F, Boccardo F, Bombardieri E et al (eds) Bone metastases from prostate cancer, 1st edn. Springer, Cham, pp 147\u2013161","edition":"1"},{"key":"5682_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-319-42327-2_14","volume-title":"Bone metastases from prostate cancer","author":"B Avuzzi","year":"2017","unstructured":"Avuzzi B, Valdagni R (2017) Bone metastases from prostate cancer: radiotherapy. In: Bertoldo F, Boccardo F, Bombardieri E et al (eds) Bone metastases from prostate cancer, 1st edn. Springer, Cham, pp 163\u2013180","edition":"1"},{"key":"5682_CR35","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2967\/jnumed.117.190827","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Calais J, Allen-Auerbach M et al (2017) 68Ga-PSMA-11 PET\/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med 58:1617\u20131623","journal-title":"J Nucl Med"},{"key":"5682_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","volume":"15","author":"S Mannweiler","year":"2009","unstructured":"Mannweiler S, Amersdorfer P, Trajanoski S et al (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15:167\u2013172","journal-title":"Pathol Oncol Res"},{"key":"5682_CR37","doi-asserted-by":"crossref","unstructured":"Fendler WP, Eiber M, Beheshti M et al (2017) 68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44:1014\u20131024","DOI":"10.1007\/s00259-017-3670-z"},{"key":"5682_CR38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J et al (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678\u2013688","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5682_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ymeth.2017.07.009","volume":"130","author":"F Ceci","year":"2017","unstructured":"Ceci F, Castellucci P, Cerci JJ, Fanti S (2017) New aspects of molecular imaging in prostate cancer. Methods 130:36\u201341","journal-title":"Methods"},{"key":"5682_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81\u201392","journal-title":"Eur Urol"},{"key":"5682_CR41","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1007\/s00259-008-0788-z","volume":"35","author":"M Beheshti","year":"2008","unstructured":"Beheshti M, Vali R, Waldenberger P et al (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35:1766\u20131774","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5682_CR42","doi-asserted-by":"crossref","unstructured":"McCarthy M, Siew T, Campbell A et al (2011) 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 38:14\u201322","DOI":"10.1007\/s00259-010-1579-x"},{"key":"5682_CR43","first-page":"155","volume":"34","author":"JR Garcia","year":"2015","unstructured":"Garcia JR, Moreno C, Valls E et al (2015) Diagnostic performance of bone scintigraphy and 11C-choline PET\/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol 34:155\u2013161","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"5682_CR44","first-page":"218","volume":"7","author":"RF Fonager","year":"2017","unstructured":"Fonager RF, Zacho HD, Langkilde NC et al (2017) Diagnostic test accuracy study of 18F-sodium fluoride PET\/CT, 99mTc-labelled diphosphonate SPECT\/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer. Am J Nucl Med Mol Imaging 7:218\u2013227","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"5682_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/0284186X.2015.1027411","volume":"55","author":"I Jambor","year":"2016","unstructured":"Jambor I, Kuisma A, Ramadan S et al (2016) Prospective evaluation of planar bone scintigraphy, SPECT, SPECT\/CT, 18F-NaF PET\/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 55:59\u201367","journal-title":"Acta Oncol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-018-5682-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T13:30:47Z","timestamp":1693834247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-018-5682-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["5682"],"URL":"https:\/\/doi.org\/10.1007\/s00330-018-5682-x","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"1 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Eva Dyrberg.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Tobias W. Klausen and Stig S. Mortensen kindly provided statistical advice for this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional review board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 prospective\u2022 diagnostic study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}